Diagnostic accuracy of bone scintigraphy imaging for transthyretin cardiac amyloidosis: systematic review and meta-analysis
Bone scintigraphy imaging is frequently used to investigate patients with suspected transthyretin cardiac amyloidosis (ATTR-CM). However, the reported accuracy for interpretation approaches has changed over time. We performed a systematic review and meta-analysis to determine the diagnostic accuracy...
Saved in:
Published in | Journal of nuclear cardiology Vol. 30; no. 6; pp. 2464 - 2476 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Cham
Elsevier Inc
01.12.2023
Springer International Publishing Springer Nature B.V |
Subjects | |
Online Access | Get full text |
ISSN | 1071-3581 1532-6551 1532-6551 |
DOI | 10.1007/s12350-023-03297-1 |
Cover
Abstract | Bone scintigraphy imaging is frequently used to investigate patients with suspected transthyretin cardiac amyloidosis (ATTR-CM). However, the reported accuracy for interpretation approaches has changed over time. We performed a systematic review and meta-analysis to determine the diagnostic accuracy of visual planar grading, heart-to-contralateral (HCL) ratio, and quantitative analysis of SPECT imaging and evaluate reasons for shifts in reported accuracy.
We performed a systematic review to identify studies of the diagnostic accuracy of bone scintigraphy for ATTR-CM from 1990 until February 2023 using PUBMED and EMBASE. Studies were reviewed separately by two authors for inclusion and for risk of bias assessment. Summary receiver operating characteristic curves and operating points were determined with hierarchical modeling.
Out of a total of 428 identified studies, 119 were reviewed in detail and 23 were included in the final analysis. The studies included a total of 3954 patients, with ATTR-CM diagnosed in 1337 (39.6%) patients and prevalence ranging from 21 to 73%. Visual planar grading and quantitative analysis had higher diagnostic accuracy (.99) than HCL ratio (.96). Quantitative analysis of SPECT imaging had the highest specificity (97%) followed by planar visual grade (96%) and HCL ratio (93%). ATTR-CM prevalence accounted for some of the observed between study heterogeneity.
Bone scintigraphy imaging is highly accurate for identifying patients with ATTR-CM, with between study heterogeneity in part explained by differences in disease prevalence. We identified small differences in specificity, which may have important clinical implications when applied to low-risk screening populations. |
---|---|
AbstractList | Bone scintigraphy imaging is frequently used to investigate patients with suspected transthyretin cardiac amyloidosis (ATTR-CM). However, the reported accuracy for interpretation approaches has changed over time. We performed a systematic review and meta-analysis to determine the diagnostic accuracy of visual planar grading, heart-to-contralateral (HCL) ratio, and quantitative analysis of SPECT imaging and evaluate reasons for shifts in reported accuracy.
We performed a systematic review to identify studies of the diagnostic accuracy of bone scintigraphy for ATTR-CM from 1990 until February 2023 using PUBMED and EMBASE. Studies were reviewed separately by two authors for inclusion and for risk of bias assessment. Summary receiver operating characteristic curves and operating points were determined with hierarchical modeling.
Out of a total of 428 identified studies, 119 were reviewed in detail and 23 were included in the final analysis. The studies included a total of 3954 patients, with ATTR-CM diagnosed in 1337 (39.6%) patients and prevalence ranging from 21 to 73%. Visual planar grading and quantitative analysis had higher diagnostic accuracy (.99) than HCL ratio (.96). Quantitative analysis of SPECT imaging had the highest specificity (97%) followed by planar visual grade (96%) and HCL ratio (93%). ATTR-CM prevalence accounted for some of the observed between study heterogeneity.
Bone scintigraphy imaging is highly accurate for identifying patients with ATTR-CM, with between study heterogeneity in part explained by differences in disease prevalence. We identified small differences in specificity, which may have important clinical implications when applied to low-risk screening populations. Background Bone scintigraphy imaging is frequently used to investigate patients with suspected transthyretin cardiac amyloidosis (ATTR-CM). However, the reported accuracy for interpretation approaches has changed over time. We performed a systematic review and meta-analysis to determine the diagnostic accuracy of visual planar grading, heart-to-contralateral (HCL) ratio, and quantitative analysis of SPECT imaging and evaluate reasons for shifts in reported accuracy. Methods We performed a systematic review to identify studies of the diagnostic accuracy of bone scintigraphy for ATTR-CM from 1990 until February 2023 using PUBMED and EMBASE. Studies were reviewed separately by two authors for inclusion and for risk of bias assessment. Summary receiver operating characteristic curves and operating points were determined with hierarchical modeling. Results Out of a total of 428 identified studies, 119 were reviewed in detail and 23 were included in the final analysis. The studies included a total of 3954 patients, with ATTR-CM diagnosed in 1337 (39.6%) patients and prevalence ranging from 21 to 73%. Visual planar grading and quantitative analysis had higher diagnostic accuracy (.99) than HCL ratio (.96). Quantitative analysis of SPECT imaging had the highest specificity (97%) followed by planar visual grade (96%) and HCL ratio (93%). ATTR-CM prevalence accounted for some of the observed between study heterogeneity. Conclusions Bone scintigraphy imaging is highly accurate for identifying patients with ATTR-CM, with between study heterogeneity in part explained by differences in disease prevalence. We identified small differences in specificity, which may have important clinical implications when applied to low-risk screening populations. BackgroundBone scintigraphy imaging is frequently used to investigate patients with suspected transthyretin cardiac amyloidosis (ATTR-CM). However, the reported accuracy for interpretation approaches has changed over time. We performed a systematic review and meta-analysis to determine the diagnostic accuracy of visual planar grading, heart-to-contralateral (HCL) ratio, and quantitative analysis of SPECT imaging and evaluate reasons for shifts in reported accuracy.MethodsWe performed a systematic review to identify studies of the diagnostic accuracy of bone scintigraphy for ATTR-CM from 1990 until February 2023 using PUBMED and EMBASE. Studies were reviewed separately by two authors for inclusion and for risk of bias assessment. Summary receiver operating characteristic curves and operating points were determined with hierarchical modeling.ResultsOut of a total of 428 identified studies, 119 were reviewed in detail and 23 were included in the final analysis. The studies included a total of 3954 patients, with ATTR-CM diagnosed in 1337 (39.6%) patients and prevalence ranging from 21 to 73%. Visual planar grading and quantitative analysis had higher diagnostic accuracy (.99) than HCL ratio (.96). Quantitative analysis of SPECT imaging had the highest specificity (97%) followed by planar visual grade (96%) and HCL ratio (93%). ATTR-CM prevalence accounted for some of the observed between study heterogeneity.ConclusionsBone scintigraphy imaging is highly accurate for identifying patients with ATTR-CM, with between study heterogeneity in part explained by differences in disease prevalence. We identified small differences in specificity, which may have important clinical implications when applied to low-risk screening populations. Bone scintigraphy imaging is frequently used to investigate patients with suspected transthyretin cardiac amyloidosis (ATTR-CM). However, the reported accuracy for interpretation approaches has changed over time. We performed a systematic review and meta-analysis to determine the diagnostic accuracy of visual planar grading, heart-to-contralateral (HCL) ratio, and quantitative analysis of SPECT imaging and evaluate reasons for shifts in reported accuracy.BACKGROUNDBone scintigraphy imaging is frequently used to investigate patients with suspected transthyretin cardiac amyloidosis (ATTR-CM). However, the reported accuracy for interpretation approaches has changed over time. We performed a systematic review and meta-analysis to determine the diagnostic accuracy of visual planar grading, heart-to-contralateral (HCL) ratio, and quantitative analysis of SPECT imaging and evaluate reasons for shifts in reported accuracy.We performed a systematic review to identify studies of the diagnostic accuracy of bone scintigraphy for ATTR-CM from 1990 until February 2023 using PUBMED and EMBASE. Studies were reviewed separately by two authors for inclusion and for risk of bias assessment. Summary receiver operating characteristic curves and operating points were determined with hierarchical modeling.METHODSWe performed a systematic review to identify studies of the diagnostic accuracy of bone scintigraphy for ATTR-CM from 1990 until February 2023 using PUBMED and EMBASE. Studies were reviewed separately by two authors for inclusion and for risk of bias assessment. Summary receiver operating characteristic curves and operating points were determined with hierarchical modeling.Out of a total of 428 identified studies, 119 were reviewed in detail and 23 were included in the final analysis. The studies included a total of 3954 patients, with ATTR-CM diagnosed in 1337 (39.6%) patients and prevalence ranging from 21 to 73%. Visual planar grading and quantitative analysis had higher diagnostic accuracy (.99) than HCL ratio (.96). Quantitative analysis of SPECT imaging had the highest specificity (97%) followed by planar visual grade (96%) and HCL ratio (93%). ATTR-CM prevalence accounted for some of the observed between study heterogeneity.RESULTSOut of a total of 428 identified studies, 119 were reviewed in detail and 23 were included in the final analysis. The studies included a total of 3954 patients, with ATTR-CM diagnosed in 1337 (39.6%) patients and prevalence ranging from 21 to 73%. Visual planar grading and quantitative analysis had higher diagnostic accuracy (.99) than HCL ratio (.96). Quantitative analysis of SPECT imaging had the highest specificity (97%) followed by planar visual grade (96%) and HCL ratio (93%). ATTR-CM prevalence accounted for some of the observed between study heterogeneity.Bone scintigraphy imaging is highly accurate for identifying patients with ATTR-CM, with between study heterogeneity in part explained by differences in disease prevalence. We identified small differences in specificity, which may have important clinical implications when applied to low-risk screening populations.CONCLUSIONSBone scintigraphy imaging is highly accurate for identifying patients with ATTR-CM, with between study heterogeneity in part explained by differences in disease prevalence. We identified small differences in specificity, which may have important clinical implications when applied to low-risk screening populations. |
Author | Jimenez-Zepeda, Victor Roshankar, Golnaz Draycott, Logan Fine, Nowell Ahluwalia, Nanki Miller, Robert J.H. Chan, Denise Han, Donghee |
Author_xml | – sequence: 1 givenname: Nanki surname: Ahluwalia fullname: Ahluwalia, Nanki organization: Department of Cardiac Sciences, University of Calgary, GAA08, 3230 Hospital Drive NW, T2N 2T9, Calgary, AB, Canada – sequence: 2 givenname: Golnaz surname: Roshankar fullname: Roshankar, Golnaz organization: Department of Cardiac Sciences, University of Calgary, GAA08, 3230 Hospital Drive NW, T2N 2T9, Calgary, AB, Canada – sequence: 3 givenname: Logan surname: Draycott fullname: Draycott, Logan organization: Department of Cardiac Sciences, University of Calgary, GAA08, 3230 Hospital Drive NW, T2N 2T9, Calgary, AB, Canada – sequence: 4 givenname: Victor surname: Jimenez-Zepeda fullname: Jimenez-Zepeda, Victor organization: Department of Hematology, University of Calgary, Calgary, AB, Canada – sequence: 5 givenname: Nowell surname: Fine fullname: Fine, Nowell organization: Department of Cardiac Sciences, University of Calgary, GAA08, 3230 Hospital Drive NW, T2N 2T9, Calgary, AB, Canada – sequence: 6 givenname: Denise surname: Chan fullname: Chan, Denise organization: Department of Nuclear Medicine, University of Calgary, Calgary, AB, Canada – sequence: 7 givenname: Donghee surname: Han fullname: Han, Donghee organization: Departments of Medicine (Division of Artificial Intelligence in Medicine), Imaging and Biomedical Sciences Cedars-Sinai Medical Center, Los Angeles, CA, USA – sequence: 8 givenname: Robert J.H. surname: Miller fullname: Miller, Robert J.H. email: robert.miller@albertahealthservices.ca organization: Department of Cardiac Sciences, University of Calgary, GAA08, 3230 Hospital Drive NW, T2N 2T9, Calgary, AB, Canada |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37226006$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kUtrFTEYhoNU7EX_gAsJuHEzmttkEnEjbb1AwY2uQyaX05SZ5JhklME_b47TInRxyCIhPM-X8L7n4CSm6AB4idFbjNDwrmBCe9QhQjtEiRw6_ASc4Z6Sjvc9PmlnNOCO9gKfgvNS7hBCkkr5DJzSgRCOED8Df66C3sVUajBQG7NkbVaYPBzbU7CYEGvYZb2_XWGY9S7EHfQpw5p1LPV2za6GCI3ONujmz-uUgk0llPewrKW6WR_mZvcruN9QRwtnV3Wno57WBj0HT72eintxv1-AH5-uv19-6W6-ff56-fGmM4yI2llv-TDyoUdecEG8tm21C4lG4pmwiOGRadZjSYUWmHkp0Mi4NNwLzJ2lF-DNNnef08_FlarmUIybJh1dWooiAksy8J6Khr5-hN6lJbf_HijJGJWIsEa9uqeWcXZW7XMLJ6_qIdYGiA0wOZWSnVcm1JZFii25MCmM1KFBtTWoWoPqX4MKN5U8Uh-mH5XoJpUGx53L_7991PqwWa6F3yrKqhXuonE2ZGeqsikc0_8CRnrCiw |
CitedBy_id | crossref_primary_10_1016_j_jfma_2024_10_008 crossref_primary_10_1007_s00259_024_06966_6 crossref_primary_10_1007_s00259_023_06576_8 crossref_primary_10_1186_s44348_024_00024_3 crossref_primary_10_1016_j_jmir_2024_02_009 crossref_primary_10_2967_jnumed_123_266926 crossref_primary_10_3390_jcm13030810 crossref_primary_10_1007_s11886_025_02202_1 crossref_primary_10_3390_jcdd11040118 crossref_primary_10_1016_j_jcmg_2023_10_010 crossref_primary_10_1007_s12350_023_03379_0 crossref_primary_10_1016_S2589_7500_24_00024_4 |
Cites_doi | 10.1016/j.hlc.2016.12.017 10.1007/s12350-019-01643-w 10.1177/1536867X0900900203 10.1093/ehjci/jeu107 10.1007/s12350-022-02960-3 10.1007/s00259-010-1642-7 10.1161/CIRCULATIONAHA.116.021612 10.1056/NEJMoa1805689 10.1161/CIRCIMAGING.112.000132 10.1001/jamacardio.2016.2839 10.1007/s12350-019-01753-5 10.1016/j.jcmg.2019.07.015 10.1161/CIRCHEARTFAILURE.119.006075 10.1016/j.jacc.2005.05.073 10.7326/0003-4819-155-8-201110180-00009 10.1186/s13550-021-00828-0 10.3109/13506129.2015.1072089 10.1016/j.jchf.2019.04.010 10.1016/j.jcmg.2020.08.027 10.1186/s41824-018-0035-1 10.1007/s12350-019-01831-8 10.1093/eurheartj/ehab072 10.1007/s12350-016-0610-4 10.1016/j.jcmg.2020.07.043 10.1161/CIRCIMAGING.119.010249 10.1007/s12350-017-0922-z 10.1007/s12350-020-02139-8 10.2967/jnumed.120.247312 10.1016/j.jcmg.2020.03.020 10.1136/bmj.327.7414.557 10.1161/CIRCULATIONAHA.118.035831 10.1016/j.cjca.2019.12.034 10.1093/eurheartj/ehv583 10.1007/s11604-022-01364-0 10.1007/s12350-021-02563-4 10.1007/s12350-022-03180-5 10.1016/j.recesp.2011.12.015 10.1007/s12350-021-02857-7 10.1016/S0735-1097(21)02708-X 10.2967/jnumed.122.264311 10.1007/s12350-021-02880-8 10.1186/s40658-020-00342-7 |
ContentType | Journal Article |
Copyright | 2023 American Society of Nuclear Cardiology. Published by ELSEVIER INC. All rights reserved. The Author(s) under exclusive licence to American Society of Nuclear Cardiology 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. 2023. The Author(s) under exclusive licence to American Society of Nuclear Cardiology. |
Copyright_xml | – notice: 2023 American Society of Nuclear Cardiology. Published by ELSEVIER INC. All rights reserved. – notice: The Author(s) under exclusive licence to American Society of Nuclear Cardiology 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. – notice: 2023. The Author(s) under exclusive licence to American Society of Nuclear Cardiology. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM K9. NAPCQ 7X8 |
DOI | 10.1007/s12350-023-03297-1 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic |
DatabaseTitleList | MEDLINE ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1532-6551 |
EndPage | 2476 |
ExternalDocumentID | 37226006 10_1007_s12350_023_03297_1 S1071358124001880 |
Genre | Meta-Analysis Systematic Review Journal Article |
GroupedDBID | --- --K -EM -Y2 .GJ 06D 0R~ 0VY 199 1B1 1N0 2.D 203 29L 29~ 2JN 2JY 2KG 2LR 2VQ 30V 3V. 4.4 406 408 40D 53G 5GY 5VS 67Z 78A 7RV 7X7 88E 8AO 8FI 8FJ 8TC 8UJ 96X AAAVM AABHQ AABYN AAEDT AAEOY AAFGU AAHNG AAIAL AAJKR AAKSU AALRI AANXM AANZL AAQFI AAQXK AARHV AARTL AATNV AATVU AAUYE AAWCG AAWTL AAXUO AAYFA AAYIU AAYQN AAYTO AAZMS ABAKF ABDZT ABECU ABFGW ABFTV ABHLI ABIPD ABJNI ABJOX ABKAS ABKCH ABMAC ABMQK ABMYL ABPLI ABQBU ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABXPI ACBMV ACBRV ACBXY ACBYP ACGFO ACGFS ACHSB ACHVE ACHXU ACIGE ACIHN ACIPQ ACKNC ACMDZ ACMLO ACOKC ACREN ACTTH ACUDM ACVWB ACWMK ACZOJ ADBBV ADHHG ADHIR ADINQ ADJJI ADKNI ADKPE ADMDM ADMUD ADOXG ADRFC ADTPH ADURQ ADYFF ADYOE ADZKW AEAQA AEBTG AEEQQ AEFQL AEFTE AEGNC AEJHL AEJRE AEKMD AENEX AEOHA AEPYU AESKC AESTI AETCA AEVLU AEVTX AEXYK AFAFS AFBBN AFKRA AFLOW AFNRJ AFQWF AFWTZ AFYQB AFZKB AGAYW AGDGC AGGBP AGGDS AGJBK AGKHE AGMZJ AGQEE AGQMX AGRTI AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIIXL AILAN AIMYW AITGF AITUG AJBLW AJDOV AJRNO AJZVZ AKMHD AKQUC AKRWK ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AMXSW AMYLF AMYQR ANMIH AOCGG ASPBG AVWKF AXYYD AZFZN BA0 BBWZM BENPR BGNMA BKEYQ BPHCQ BVXVI CAG CCPQU COF CS3 CSCUP DDRTE DNIVK DPUIP DU5 EBD EBLON EBS EIOEI EJD EMOBN EN4 EO8 EO9 ESBYG EX3 F5P FDB FEDTE FERAY FFXSO FGOYB FIGPU FINBP FNLPD FRRFC FSGXE FYUFA G-Q GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GRRUI HF~ HG6 HMCUK HMJXF HRMNR HVGLF HZ~ IHE IKXTQ IMOTQ ITM IWAJR IXC I~X J-C J0Z J5H JBSCW JZLTJ KOV KPH LLZTM M1P M41 M4Y MA- N2Q N9A NAPCQ NDZJH NF0 NQ- NQJWS NU0 O9- O93 O9G O9I O9J P19 P2P P9S PQQKQ PROAC PSQYO PT4 PT5 Q2X R2- R89 R9I RHV RIG RNI ROL RPZ RSV RZK S1Z S26 S27 S28 S37 S3B SCLPG SDE SDG SDH SEW SHX SISQX SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD SSZ STPWE SV3 SZ9 SZN T13 T16 TSG TT1 U2A U9L UG4 UKHRP UNUBA UOJIU UTJUX UZXMN VC2 VFIZW W48 WK8 WOW Z45 Z7U Z7X Z7Y Z82 Z87 ZMTXR ZOVNA ~A9 AAJBT AAYZH ABQSL ABWVN ACRPL ADNMO AFJKZ ALIPV AMRAJ H13 NPVJJ SJN AAYXX ABFSG ACSTC ADHKG AEZWR AFHIU AGCQF AGQPQ AHPBZ AHWEU AIGII AIXLP APXCP AYFIA CITATION PHGZM PHGZT CGR CUY CVF ECM EIF NPM EFKBS K9. 7X8 |
ID | FETCH-LOGICAL-c428t-dfd67b6750f8682fadada7b690b2f48d041b4a451938a814f980b469c6f816ed3 |
IEDL.DBID | AGYKE |
ISSN | 1071-3581 1532-6551 |
IngestDate | Sun Sep 28 12:16:45 EDT 2025 Wed Aug 13 07:02:44 EDT 2025 Thu Apr 03 07:07:25 EDT 2025 Tue Jul 01 01:28:53 EDT 2025 Thu Apr 24 23:08:02 EDT 2025 Fri Feb 21 02:44:17 EST 2025 Sat Mar 16 16:14:37 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Keywords | HCL HMDP Meta analysis SROC CI PYP ATTR-CM DPD Amyloid heart disease SPECT AUC |
Language | English |
License | 2023. The Author(s) under exclusive licence to American Society of Nuclear Cardiology. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c428t-dfd67b6750f8682fadada7b690b2f48d041b4a451938a814f980b469c6f816ed3 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-3 ObjectType-Evidence Based Healthcare-1 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 |
PMID | 37226006 |
PQID | 2894439024 |
PQPubID | 54088 |
PageCount | 13 |
ParticipantIDs | proquest_miscellaneous_2819276538 proquest_journals_2894439024 pubmed_primary_37226006 crossref_citationtrail_10_1007_s12350_023_03297_1 crossref_primary_10_1007_s12350_023_03297_1 springer_journals_10_1007_s12350_023_03297_1 elsevier_sciencedirect_doi_10_1007_s12350_023_03297_1 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2023-12-01 |
PublicationDateYYYYMMDD | 2023-12-01 |
PublicationDate_xml | – month: 12 year: 2023 text: 2023-12-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | Cham |
PublicationPlace_xml | – name: Cham – name: United States – name: New York |
PublicationTitle | Journal of nuclear cardiology |
PublicationTitleAbbrev | J. Nucl. Cardiol |
PublicationTitleAlternate | J Nucl Cardiol |
PublicationYear | 2023 |
Publisher | Elsevier Inc Springer International Publishing Springer Nature B.V |
Publisher_xml | – name: Elsevier Inc – name: Springer International Publishing – name: Springer Nature B.V |
References | Sperry BW, Bateman TM, Akin EA, Bravo PE, Chen W, Dilsizian V et al. Hot spot imaging in cardiovascular diseases: an information statement from SNMMI, ASNC, and EANM. J Nucl Cardiol 2022 Witteles, Bokhari, Damy, Elliott, Falk, Fine (bib20) 2019; 7 Roshankar G, White GC, Cadet S, Fine NM, Chan D, White JA et al. Quantitative technetium pyrophosphate and cardiovascular magnetic resonance in patients with suspected cardiac amyloidosis. J Nucl Cardiol 2021. Galat, Rosso, Guellich, Van Der Gucht, Rappeneau, Bodez (bib36) 2015; 22 Masri, Bukhari, Ahmad, Nieves, Eisele, Follansbee (bib41) 2020; 13 Poterucha, Elias, Bokhari, Einstein, DeLuca, Kinkhabwala (bib9) 2021; 14 Hutt, Quigley, Page, Hall, Burniston, Gopaul (bib35) 2014; 15 Moore, Burrage, Mackenzie, Law, Korczyk, Mollee (bib37) 2017; 26 Ikoma T, Ohtani H, Ohno K, Iguchi K, Suwa K, Sawada M et al. Diagnostic value of heart-to-mediastinum ratio in (99m)Tc-pyrophospate SPECT/CT for transthyretin cardiac amyloidosis. J Nucl Cardiol 2022 Harbord, Whiting (bib16) 2009; 9 Bokhari, Morgenstern, Weinberg, Kinkhabwala, Panagiotou, Castano (bib18) 2018; 25 de Haro-del Moral, Sánchez-Lajusticia, Gómez-Bueno, García-Pavía, Salas-Antón, Segovia-Cubero (bib33) 2012; 65 Miller RJH, Cadet S, Mah D, Pournazari P, Chan D, Fine NM et al. Diagnostic and prognostic value of Technetium-99m pyrophosphate uptake quantitation for transthyretin cardiac amyloidosis. J Nucl Cardiol 2021. Maurer, Bokhari, Damy, Dorbala, Drachman, Fontana (bib8) 2019; 12 Maurer, Schwartz, Gundapaneni, Elliott, Merlini, Waddington-Cruz (bib3) 2018; 379 Dorbala, Ando, Bokhari, Dispenzieri, Falk, Ferrari (bib5) 2021; 14 Watanabe S, Nakajima K, Hiroshi W, et al. Volumetric evaluation of 99mTc-pyrophosphate SPECT/CT for transthyretin cardiac amyloidosis: methodology and correlation with cardiac functional parameters. J Nucl Cardiol 2021 Higgins, Thompson, Deeks, Altman (bib14) 2003; 327 Matsuda N, Otsuka H, Otani T, Azane S, Kunikane Y, Otomi Y et al. New quantitative indices of cardiac amyloidosis with 99mTc-pyrophosphate scintigraphy. Japanese J Radiol 2022 Gillmore, Maurer, Falk, Merlini, Damy, Dispenzieri (bib7) 2016; 133 Ren C, Ren J, Tian Z, Du Y, Hao Z, Zhang Z et al. Assessment of cardiac amyloidosis with (99m)Tc-pyrophosphate (PYP) quantitative SPECT. EJNMMI Phys 2021;8:3 Flaherty, Morgenstern, Pozniakoff, DeLuca, Castano, Maurer (bib40) 2020; 27 Tamarappoo, Otaki, Manabe, Hyun, Cantu, Arnson (bib43) 2020; 27 Ben-Haim, Chicheportiche, Goshen, Arad, Smekhov, Menezes (bib26) 2021; 11 Miller RJH, Fine N. Quantifying is believing: techniques for evaluating transthyretin cardiac amyloidosis burden for expanded clinical applications. J Nucl Cardiol 2021 Bokhari, Castaño, Pozniakoff, Deslisle, Latif, Maurer (bib34) 2013; 6 Whiting, Rutjes, Westwood, Mallett, Deeks, Reitsma (bib13) 2011; 155 Solomon, Adams, Kristen, Grogan, González-Duarte, Maurer (bib17) 2019; 139 Ramsay, Lindsay, Fong, Patford, Younger, Atherton (bib29) 2018; 2 Kessler, Fragoso Costa, Kersting, Jentzen, Weber, Lüdike (bib45) 2023; 30 Garcia-Pavia, Rapezzi, Adler, Arad, Basso, Brucato (bib2) 2021; 42 Coelho, Adams, Conceição, Waddington-Cruz, Schmidt, Buades (bib4) 2020; 15 Dorbala, Cuddy, Falk (bib12) 2020; 13 Dorbala, Park, Cuddy, Singh, Sullivan, Kim (bib25) 2021; 62 Rapezzi, Quarta, Guidalotti, Longhi, Pettinato, Leone (bib32) 2011; 38 Sperry, Burgett, Bybee, McGhie, O’Keefe, Saeed (bib42) 2020; 27 Perugini, Guidalotti, Salvi, Cooke, Pettinato, Riva (bib10) 2005; 46 Bokhari, Castano, Pozniakoff, Deslisle, Latif, Maurer (bib11) 2013; 6 Fontana, Martinez-Naharro, Chacko, Rowczenio, Gilbertson, Whelan (bib31) 2021; 14 Poterucha, Elias, Bokhari, Einstein, DeLuca, Kinkhabwala (bib19) 2021; 14 Scully, Morris, Patel, Treibel, Burniston, Klotz (bib28) 2020; 13 Damy, Costes, Hagège, Donal, Eicher, Slama (bib21) 2015; 37 Gallini, Tutino, Martone, Ciaccio, Costanzo, Taborchi (bib39) 2021; 28 Cappelli, Gallini, Di Mario, Costanzo, Vaggelli, Tutino (bib38) 2019; 26 Castano, Haq, Narotsky, Goldsmith, Weinberg, Morgenstern (bib15) 2016; 1 Fine, Davis, Anderson, Delgado, Giraldeau, Kitchlu (bib1) 2020; 36 Gillmore, Maurer, Falk, Merlini, Damy, Dispenzieri (CR7) 2016; 133 Scully, Morris, Patel, Treibel, Burniston, Klotz (CR28) 2020; 13 Ramsay, Lindsay, Fong, Patford, Younger, Atherton (CR29) 2018; 2 Masri, Bukhari, Ahmad, Nieves, Eisele, Follansbee (CR41) 2020; 13 Cappelli, Gallini, Di Mario, Costanzo, Vaggelli, Tutino (CR38) 2019; 26 Dorbala, Ando, Bokhari, Dispenzieri, Falk, Ferrari (CR5) 2021; 14 de Haro-del Moral, Sánchez-Lajusticia, Gómez-Bueno, García-Pavía, Salas-Antón, Segovia-Cubero (CR33) 2012; 65 Perugini, Guidalotti, Salvi, Cooke, Pettinato, Riva (CR10) 2005; 46 Kessler, Fragoso Costa, Kersting, Jentzen, Weber, Lüdike (CR45) 2023; 30 Rapezzi, Quarta, Guidalotti, Longhi, Pettinato, Leone (CR32) 2011; 38 Castano, Haq, Narotsky, Goldsmith, Weinberg, Morgenstern (CR15) 2016; 1 CR30 Maurer, Schwartz, Gundapaneni, Elliott, Merlini, Waddington-Cruz (CR3) 2018; 379 Solomon, Adams, Kristen, Grogan, González-Duarte, Maurer (CR17) 2019; 139 Moore, Burrage, Mackenzie, Law, Korczyk, Mollee (CR37) 2017; 26 Fontana, Martinez-Naharro, Chacko, Rowczenio, Gilbertson, Whelan (CR31) 2021; 14 Poterucha, Elias, Bokhari, Einstein, DeLuca, Kinkhabwala (CR9) 2021; 14 Galat, Rosso, Guellich, Van Der Gucht, Rappeneau, Bodez (CR36) 2015; 22 Witteles, Bokhari, Damy, Elliott, Falk, Fine (CR20) 2019; 7 Bokhari, Castano, Pozniakoff, Deslisle, Latif, Maurer (CR11) 2013; 6 Ben-Haim, Chicheportiche, Goshen, Arad, Smekhov, Menezes (CR26) 2021; 11 Sperry, Burgett, Bybee, McGhie, O'Keefe, Saeed (CR42) 2020; 27 CR6 Fine, Davis, Anderson, Delgado, Giraldeau, Kitchlu (CR1) 2020; 36 Tamarappoo, Otaki, Manabe, Hyun, Cantu, Arnson (CR43) 2020; 27 Coelho, Adams, Conceição, Waddington-Cruz, Schmidt, Buades (CR4) 2020; 15 CR27 Dorbala, Park, Cuddy, Singh, Sullivan, Kim (CR25) 2021; 62 Bokhari, Morgenstern, Weinberg, Kinkhabwala, Panagiotou, Castano (CR18) 2018; 25 Poterucha, Elias, Bokhari, Einstein, DeLuca, Kinkhabwala (CR19) 2021; 14 Damy, Costes, Hagège, Donal, Eicher, Slama (CR21) 2015; 37 CR24 CR46 CR23 Bokhari, Castaño, Pozniakoff, Deslisle, Latif, Maurer (CR34) 2013; 6 CR22 CR44 Harbord, Whiting (CR16) 2009; 9 Maurer, Bokhari, Damy, Dorbala, Drachman, Fontana (CR8) 2019; 12 Dorbala, Cuddy, Falk (CR12) 2020; 13 Hutt, Quigley, Page, Hall, Burniston, Gopaul (CR35) 2014; 15 Whiting, Rutjes, Westwood, Mallett, Deeks, Reitsma (CR13) 2011; 155 Flaherty, Morgenstern, Pozniakoff, DeLuca, Castano, Maurer (CR40) 2020; 27 Garcia-Pavia, Rapezzi, Adler, Arad, Basso, Brucato (CR2) 2021; 42 Higgins, Thompson, Deeks, Altman (CR14) 2003; 327 Gallini, Tutino, Martone, Ciaccio, Costanzo, Taborchi (CR39) 2021; 28 10.1007/s12350-023-03297-1_bib22 10.1007/s12350-023-03297-1_bib44 10.1007/s12350-023-03297-1_bib23 Ramsay (10.1007/s12350-023-03297-1_bib29) 2018; 2 Maurer (10.1007/s12350-023-03297-1_bib8) 2019; 12 10.1007/s12350-023-03297-1_bib24 Bokhari (10.1007/s12350-023-03297-1_bib34) 2013; 6 10.1007/s12350-023-03297-1_bib46 Poterucha (10.1007/s12350-023-03297-1_bib19) 2021; 14 10.1007/s12350-023-03297-1_bib27 Moore (10.1007/s12350-023-03297-1_bib37) 2017; 26 Dorbala (10.1007/s12350-023-03297-1_bib5) 2021; 14 Witteles (10.1007/s12350-023-03297-1_bib20) 2019; 7 Gallini (10.1007/s12350-023-03297-1_bib39) 2021; 28 Maurer (10.1007/s12350-023-03297-1_bib3) 2018; 379 Galat (10.1007/s12350-023-03297-1_bib36) 2015; 22 Harbord (10.1007/s12350-023-03297-1_bib16) 2009; 9 Bokhari (10.1007/s12350-023-03297-1_bib18) 2018; 25 Bokhari (10.1007/s12350-023-03297-1_bib11) 2013; 6 Castano (10.1007/s12350-023-03297-1_bib15) 2016; 1 de Haro-del Moral (10.1007/s12350-023-03297-1_bib33) 2012; 65 Flaherty (10.1007/s12350-023-03297-1_bib40) 2020; 27 Higgins (10.1007/s12350-023-03297-1_bib14) 2003; 327 Coelho (10.1007/s12350-023-03297-1_bib4) 2020; 15 Fontana (10.1007/s12350-023-03297-1_bib31) 2021; 14 Dorbala (10.1007/s12350-023-03297-1_bib12) 2020; 13 Ben-Haim (10.1007/s12350-023-03297-1_bib26) 2021; 11 Cappelli (10.1007/s12350-023-03297-1_bib38) 2019; 26 Garcia-Pavia (10.1007/s12350-023-03297-1_bib2) 2021; 42 Kessler (10.1007/s12350-023-03297-1_bib45) 2023; 30 Gillmore (10.1007/s12350-023-03297-1_bib7) 2016; 133 Poterucha (10.1007/s12350-023-03297-1_bib9) 2021; 14 Rapezzi (10.1007/s12350-023-03297-1_bib32) 2011; 38 Perugini (10.1007/s12350-023-03297-1_bib10) 2005; 46 Masri (10.1007/s12350-023-03297-1_bib41) 2020; 13 Dorbala (10.1007/s12350-023-03297-1_bib25) 2021; 62 Damy (10.1007/s12350-023-03297-1_bib21) 2015; 37 10.1007/s12350-023-03297-1_bib30 Scully (10.1007/s12350-023-03297-1_bib28) 2020; 13 Whiting (10.1007/s12350-023-03297-1_bib13) 2011; 155 Tamarappoo (10.1007/s12350-023-03297-1_bib43) 2020; 27 Solomon (10.1007/s12350-023-03297-1_bib17) 2019; 139 Sperry (10.1007/s12350-023-03297-1_bib42) 2020; 27 Fine (10.1007/s12350-023-03297-1_bib1) 2020; 36 10.1007/s12350-023-03297-1_bib6 Hutt (10.1007/s12350-023-03297-1_bib35) 2014; 15 |
References_xml | – volume: 379 start-page: 1007 year: 2018 end-page: 1016 ident: bib3 article-title: Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy publication-title: N Engl J Med – volume: 133 start-page: 2404 year: 2016 end-page: 2412 ident: bib7 article-title: Nonbiopsy diagnosis of cardiac transthyretin amyloidosis publication-title: Circulation – reference: Matsuda N, Otsuka H, Otani T, Azane S, Kunikane Y, Otomi Y et al. New quantitative indices of cardiac amyloidosis with 99mTc-pyrophosphate scintigraphy. Japanese J Radiol 2022 – reference: Sperry BW, Bateman TM, Akin EA, Bravo PE, Chen W, Dilsizian V et al. Hot spot imaging in cardiovascular diseases: an information statement from SNMMI, ASNC, and EANM. J Nucl Cardiol 2022 – volume: 14 start-page: 1221 year: 2021 end-page: 1231 ident: bib9 article-title: Diagnosing transthyretin cardiac amyloidosis by technetium Tc 99m pyrophosphate: a test in evolution publication-title: JACC Cardiovasc Imaging – volume: 6 start-page: 195 year: 2013 end-page: 201 ident: bib34 article-title: Pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses publication-title: Circ Cardiovasc Imaging – volume: 6 start-page: 195 year: 2013 end-page: 201 ident: bib11 article-title: (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses publication-title: Circ Cardiovasc Imaging – volume: 327 start-page: 557 year: 2003 end-page: 560 ident: bib14 article-title: Measuring inconsistency in meta-analyses publication-title: BMJ – volume: 139 start-page: 431 year: 2019 end-page: 443 ident: bib17 article-title: Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis publication-title: Circulation – reference: Watanabe S, Nakajima K, Hiroshi W, et al. Volumetric evaluation of 99mTc-pyrophosphate SPECT/CT for transthyretin cardiac amyloidosis: methodology and correlation with cardiac functional parameters. J Nucl Cardiol 2021 – reference: Miller RJH, Cadet S, Mah D, Pournazari P, Chan D, Fine NM et al. Diagnostic and prognostic value of Technetium-99m pyrophosphate uptake quantitation for transthyretin cardiac amyloidosis. J Nucl Cardiol 2021. – volume: 30 start-page: 101 year: 2023 end-page: 111 ident: bib45 article-title: Quantitative (99m)Tc-DPD-SPECT/CT assessment of cardiac amyloidosis publication-title: J Nucl Cardiol – reference: Ikoma T, Ohtani H, Ohno K, Iguchi K, Suwa K, Sawada M et al. Diagnostic value of heart-to-mediastinum ratio in (99m)Tc-pyrophospate SPECT/CT for transthyretin cardiac amyloidosis. J Nucl Cardiol 2022 – volume: 14 start-page: 1221 year: 2021 end-page: 1231 ident: bib19 article-title: Diagnosing transthyretin cardiac amyloidosis by Technetium Tc 99m pyrophosphate publication-title: JACC – volume: 2 start-page: 17 year: 2018 ident: bib29 article-title: Tc-HDP quantitative SPECT/CT in transthyretin cardiac amyloid and the development of a reference interval for myocardial uptake in the non-affected population publication-title: Eur J Hybrid Imaging – volume: 13 start-page: 1353 year: 2020 end-page: 1363 ident: bib28 article-title: DPD quantification in cardiac amyloidosis publication-title: JACC Cardiovasc Imaging – volume: 155 start-page: 529 year: 2011 end-page: 536 ident: bib13 article-title: QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies publication-title: Ann Intern Med – volume: 12 year: 2019 ident: bib8 article-title: Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis publication-title: Circ Heart Fail – volume: 15 start-page: 179 year: 2020 ident: bib4 article-title: A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis publication-title: J Rare Dis – volume: 42 start-page: 1554 year: 2021 end-page: 1568 ident: bib2 article-title: Diagnosis and treatment of cardiac amyloidosis publication-title: Eur Heart J – volume: 27 start-page: 1802 year: 2020 end-page: 1807 ident: bib42 article-title: Technetium pyrophosphate nuclear scintigraphy for cardiac amyloidosis: imaging at 1 vs 3 hours and planar vs SPECT/CT publication-title: J Nucl Cardiol – volume: 62 start-page: 716 year: 2021 end-page: 722 ident: bib25 article-title: Absolute quantitation of cardiac (99m)Tc-pyrophosphate using cadmium-zinc-telluride-based SPECT/CT publication-title: J Nucl Med – volume: 14 year: 2021 ident: bib5 article-title: ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2—evidence base and standardized methods of imaging publication-title: Circ Cardiovasc Imaging – volume: 11 start-page: 86 year: 2021 ident: bib26 article-title: Quantitative SPECT/CT parameters of myocardial 99mTechnetium-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) uptake in suspected cardiac transthyretin amyloidosis publication-title: EJNMMI Res – volume: 27 start-page: 28 year: 2020 end-page: 37 ident: bib43 article-title: Simultaneous Tc-99m PYP/Tl-201 dual-isotope SPECT myocardial imaging in patients with suspected cardiac amyloidosis publication-title: J Nucl Cardiol – volume: 37 start-page: 1826 year: 2015 end-page: 1834 ident: bib21 article-title: Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness publication-title: Eur Heart J – volume: 38 start-page: 470 year: 2011 end-page: 478 ident: bib32 article-title: Usefulness and limitations of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy publication-title: Eur J Nucl Med Mol Imaging – volume: 1 start-page: 880 year: 2016 end-page: 889 ident: bib15 article-title: Multicenter study of planar technetium 99m pyrophosphate cardiac imaging publication-title: JAMA Cardiol – volume: 36 start-page: 322 year: 2020 end-page: 334 ident: bib1 article-title: CCS/CHFS joint position statement on the evaluation and management of patients with cardiac amyloidosis publication-title: Can J Cardiol – volume: 14 start-page: 189 year: 2021 end-page: 199 ident: bib31 article-title: Reduction in CMR derived extracellular volume with patisiran indicates cardiac amyloid regression publication-title: JACC Cardiovasc Imaging – reference: Roshankar G, White GC, Cadet S, Fine NM, Chan D, White JA et al. Quantitative technetium pyrophosphate and cardiovascular magnetic resonance in patients with suspected cardiac amyloidosis. J Nucl Cardiol 2021. – reference: Ren C, Ren J, Tian Z, Du Y, Hao Z, Zhang Z et al. Assessment of cardiac amyloidosis with (99m)Tc-pyrophosphate (PYP) quantitative SPECT. EJNMMI Phys 2021;8:3 – volume: 22 start-page: 210 year: 2015 end-page: 220 ident: bib36 article-title: Usefulness of (99m)Tc-HMDP scintigraphy for the etiologic diagnosis and prognosis of cardiac amyloidosis publication-title: Amyloid – volume: 46 start-page: 1076 year: 2005 end-page: 1084 ident: bib10 article-title: Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy publication-title: J Am Coll Cardiol – volume: 13 start-page: 1368 year: 2020 end-page: 1383 ident: bib12 article-title: How to image cardiac amyloidosis: a practical approach publication-title: JACC Cardiovasc Imaging – volume: 26 start-page: 497 year: 2019 end-page: 504 ident: bib38 article-title: Accuracy of 99mTc-Hydroxymethylene diphosphonate scintigraphy for diagnosis of transthyretin cardiac amyloidosis publication-title: J Nucl Cardiol – volume: 9 start-page: 211 year: 2009 end-page: 229 ident: bib16 article-title: Metandi: meta-analysis of diagnostic accuracy using hierarchical logistic regression publication-title: STATA J – volume: 27 start-page: 371 year: 2020 end-page: 380 ident: bib40 article-title: 99mTechnetium pyrophosphate scintigraphy with cadmium zinc telluride cameras is a highly sensitive and specific imaging modality to diagnose transthyretin cardiac amyloidosis publication-title: J Nucl Cardiol – volume: 65 start-page: 440 year: 2012 end-page: 446 ident: bib33 article-title: Role of cardiac scintigraphy with publication-title: Rev Esp Cardiol – volume: 26 start-page: 1183 year: 2017 end-page: 1190 ident: bib37 article-title: The utility of (99m)Tc-DPD scintigraphy in the diagnosis of cardiac amyloidosis publication-title: Heart Lung Circ – reference: Miller RJH, Fine N. Quantifying is believing: techniques for evaluating transthyretin cardiac amyloidosis burden for expanded clinical applications. J Nucl Cardiol 2021 – volume: 13 year: 2020 ident: bib41 article-title: Efficient 1-hour Technetium-99 m pyrophosphate imaging protocol for the diagnosis of transthyretin cardiac amyloidosis publication-title: Circ Cardiovasc Imaging – volume: 7 start-page: 709 year: 2019 end-page: 716 ident: bib20 article-title: Screening for transthyretin amyloid cardiomyopathy in everyday practice publication-title: JACC Heart Fail – volume: 15 start-page: 1289 year: 2014 end-page: 1298 ident: bib35 article-title: Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis publication-title: Eur Heart J Cardiovasc Imaging – volume: 25 start-page: 181 year: 2018 end-page: 190 ident: bib18 article-title: Standardization of Technetium pyrophosphate imaging methodology to diagnose TTR cardiac amyloidosis publication-title: J Nucl Cardiol – volume: 28 start-page: 90 year: 2021 end-page: 99 ident: bib39 article-title: Semi-quantitative indices of cardiac uptake in patients with suspected cardiac amyloidosis undergoing 99mTc-HMDP scintigraphy publication-title: J Nucl Cardiol – ident: CR22 – volume: 26 start-page: 1183 year: 2017 end-page: 1190 ident: CR37 article-title: The utility of (99m)Tc-DPD scintigraphy in the diagnosis of cardiac amyloidosis publication-title: Heart Lung Circ doi: 10.1016/j.hlc.2016.12.017 – volume: 28 start-page: 90 year: 2021 end-page: 99 ident: CR39 article-title: Semi-quantitative indices of cardiac uptake in patients with suspected cardiac amyloidosis undergoing 99mTc-HMDP scintigraphy publication-title: J Nucl Cardiol doi: 10.1007/s12350-019-01643-w – volume: 9 start-page: 211 year: 2009 end-page: 229 ident: CR16 article-title: Metandi: meta-analysis of diagnostic accuracy using hierarchical logistic regression publication-title: STATA J doi: 10.1177/1536867X0900900203 – volume: 15 start-page: 1289 year: 2014 end-page: 1298 ident: CR35 article-title: Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis publication-title: Eur Heart J Cardiovasc Imaging doi: 10.1093/ehjci/jeu107 – volume: 30 start-page: 101 year: 2023 end-page: 111 ident: CR45 article-title: Quantitative (99m)Tc-DPD-SPECT/CT assessment of cardiac amyloidosis publication-title: J Nucl Cardiol doi: 10.1007/s12350-022-02960-3 – volume: 38 start-page: 470 year: 2011 end-page: 478 ident: CR32 article-title: Usefulness and limitations of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy publication-title: Eur J Nucl Med Mol Imaging doi: 10.1007/s00259-010-1642-7 – volume: 133 start-page: 2404 year: 2016 end-page: 2412 ident: CR7 article-title: Nonbiopsy diagnosis of cardiac transthyretin amyloidosis publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.116.021612 – volume: 379 start-page: 1007 year: 2018 end-page: 1016 ident: CR3 article-title: Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy publication-title: N Engl J Med doi: 10.1056/NEJMoa1805689 – volume: 6 start-page: 195 year: 2013 end-page: 201 ident: CR11 article-title: (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses publication-title: Circ Cardiovasc Imaging doi: 10.1161/CIRCIMAGING.112.000132 – volume: 14 start-page: 1221 year: 2021 end-page: 1231 ident: CR19 article-title: Diagnosing transthyretin cardiac amyloidosis by Technetium Tc 99m pyrophosphate publication-title: JACC – ident: CR30 – volume: 1 start-page: 880 year: 2016 end-page: 889 ident: CR15 article-title: Multicenter study of planar technetium 99m pyrophosphate cardiac imaging publication-title: JAMA Cardiol doi: 10.1001/jamacardio.2016.2839 – volume: 27 start-page: 28 year: 2020 end-page: 37 ident: CR43 article-title: Simultaneous Tc-99m PYP/Tl-201 dual-isotope SPECT myocardial imaging in patients with suspected cardiac amyloidosis publication-title: J Nucl Cardiol doi: 10.1007/s12350-019-01753-5 – volume: 13 start-page: 1368 year: 2020 end-page: 1383 ident: CR12 article-title: How to image cardiac amyloidosis: a practical approach publication-title: JACC Cardiovasc Imaging doi: 10.1016/j.jcmg.2019.07.015 – volume: 12 year: 2019 ident: CR8 article-title: Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis publication-title: Circ Heart Fail doi: 10.1161/CIRCHEARTFAILURE.119.006075 – volume: 46 start-page: 1076 year: 2005 end-page: 1084 ident: CR10 article-title: Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2005.05.073 – volume: 155 start-page: 529 year: 2011 end-page: 536 ident: CR13 article-title: QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies publication-title: Ann Intern Med doi: 10.7326/0003-4819-155-8-201110180-00009 – ident: CR6 – volume: 11 start-page: 86 year: 2021 ident: CR26 article-title: Quantitative SPECT/CT parameters of myocardial 99mTechnetium-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) uptake in suspected cardiac transthyretin amyloidosis publication-title: EJNMMI Res doi: 10.1186/s13550-021-00828-0 – ident: CR27 – volume: 22 start-page: 210 year: 2015 end-page: 220 ident: CR36 article-title: Usefulness of (99m)Tc-HMDP scintigraphy for the etiologic diagnosis and prognosis of cardiac amyloidosis publication-title: Amyloid doi: 10.3109/13506129.2015.1072089 – volume: 7 start-page: 709 year: 2019 end-page: 716 ident: CR20 article-title: Screening for transthyretin amyloid cardiomyopathy in everyday practice publication-title: JACC Heart Fail doi: 10.1016/j.jchf.2019.04.010 – ident: CR23 – volume: 14 start-page: 1221 year: 2021 end-page: 1231 ident: CR9 article-title: Diagnosing transthyretin cardiac amyloidosis by technetium Tc 99m pyrophosphate: a test in evolution publication-title: JACC Cardiovasc Imaging doi: 10.1016/j.jcmg.2020.08.027 – volume: 2 start-page: 17 year: 2018 ident: CR29 article-title: Tc-HDP quantitative SPECT/CT in transthyretin cardiac amyloid and the development of a reference interval for myocardial uptake in the non-affected population publication-title: Eur J Hybrid Imaging doi: 10.1186/s41824-018-0035-1 – volume: 27 start-page: 371 year: 2020 end-page: 380 ident: CR40 article-title: 99mTechnetium pyrophosphate scintigraphy with cadmium zinc telluride cameras is a highly sensitive and specific imaging modality to diagnose transthyretin cardiac amyloidosis publication-title: J Nucl Cardiol doi: 10.1007/s12350-019-01831-8 – ident: CR46 – volume: 42 start-page: 1554 year: 2021 end-page: 1568 ident: CR2 article-title: Diagnosis and treatment of cardiac amyloidosis publication-title: Eur Heart J doi: 10.1093/eurheartj/ehab072 – volume: 25 start-page: 181 year: 2018 end-page: 190 ident: CR18 article-title: Standardization of Technetium pyrophosphate imaging methodology to diagnose TTR cardiac amyloidosis publication-title: J Nucl Cardiol doi: 10.1007/s12350-016-0610-4 – volume: 14 start-page: 189 year: 2021 end-page: 199 ident: CR31 article-title: Reduction in CMR derived extracellular volume with patisiran indicates cardiac amyloid regression publication-title: JACC Cardiovasc Imaging doi: 10.1016/j.jcmg.2020.07.043 – volume: 13 year: 2020 ident: CR41 article-title: Efficient 1-hour Technetium-99 m pyrophosphate imaging protocol for the diagnosis of transthyretin cardiac amyloidosis publication-title: Circ Cardiovasc Imaging doi: 10.1161/CIRCIMAGING.119.010249 – ident: CR44 – volume: 65 start-page: 440 year: 2012 end-page: 446 ident: CR33 article-title: Role of cardiac scintigraphy with mTc-DPD in the differentiation of cardiac amyloidosis subtype publication-title: Rev Esp Cardiol – volume: 26 start-page: 497 year: 2019 end-page: 504 ident: CR38 article-title: Accuracy of 99mTc-Hydroxymethylene diphosphonate scintigraphy for diagnosis of transthyretin cardiac amyloidosis publication-title: J Nucl Cardiol doi: 10.1007/s12350-017-0922-z – volume: 27 start-page: 1802 year: 2020 end-page: 1807 ident: CR42 article-title: Technetium pyrophosphate nuclear scintigraphy for cardiac amyloidosis: imaging at 1 vs 3 hours and planar vs SPECT/CT publication-title: J Nucl Cardiol doi: 10.1007/s12350-020-02139-8 – volume: 62 start-page: 716 year: 2021 end-page: 722 ident: CR25 article-title: Absolute quantitation of cardiac (99m)Tc-pyrophosphate using cadmium-zinc-telluride-based SPECT/CT publication-title: J Nucl Med doi: 10.2967/jnumed.120.247312 – volume: 13 start-page: 1353 year: 2020 end-page: 1363 ident: CR28 article-title: DPD quantification in cardiac amyloidosis publication-title: JACC Cardiovasc Imaging doi: 10.1016/j.jcmg.2020.03.020 – volume: 15 start-page: 179 year: 2020 ident: CR4 article-title: A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis publication-title: J Rare Dis – volume: 14 year: 2021 ident: CR5 article-title: ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2—evidence base and standardized methods of imaging publication-title: Circ Cardiovasc Imaging – volume: 327 start-page: 557 year: 2003 end-page: 560 ident: CR14 article-title: Measuring inconsistency in meta-analyses publication-title: BMJ doi: 10.1136/bmj.327.7414.557 – volume: 139 start-page: 431 year: 2019 end-page: 443 ident: CR17 article-title: Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.118.035831 – volume: 6 start-page: 195 year: 2013 end-page: 201 ident: CR34 article-title: Pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses publication-title: Circ Cardiovasc Imaging doi: 10.1161/CIRCIMAGING.112.000132 – ident: CR24 – volume: 36 start-page: 322 year: 2020 end-page: 334 ident: CR1 article-title: CCS/CHFS joint position statement on the evaluation and management of patients with cardiac amyloidosis publication-title: Can J Cardiol doi: 10.1016/j.cjca.2019.12.034 – volume: 37 start-page: 1826 year: 2015 end-page: 1834 ident: CR21 article-title: Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness publication-title: Eur Heart J doi: 10.1093/eurheartj/ehv583 – volume: 139 start-page: 431 year: 2019 ident: 10.1007/s12350-023-03297-1_bib17 article-title: Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.118.035831 – volume: 13 year: 2020 ident: 10.1007/s12350-023-03297-1_bib41 article-title: Efficient 1-hour Technetium-99 m pyrophosphate imaging protocol for the diagnosis of transthyretin cardiac amyloidosis publication-title: Circ Cardiovasc Imaging doi: 10.1161/CIRCIMAGING.119.010249 – volume: 6 start-page: 195 year: 2013 ident: 10.1007/s12350-023-03297-1_bib34 article-title: Pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses publication-title: Circ Cardiovasc Imaging doi: 10.1161/CIRCIMAGING.112.000132 – ident: 10.1007/s12350-023-03297-1_bib46 doi: 10.1007/s11604-022-01364-0 – volume: 133 start-page: 2404 year: 2016 ident: 10.1007/s12350-023-03297-1_bib7 article-title: Nonbiopsy diagnosis of cardiac transthyretin amyloidosis publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.116.021612 – volume: 7 start-page: 709 year: 2019 ident: 10.1007/s12350-023-03297-1_bib20 article-title: Screening for transthyretin amyloid cardiomyopathy in everyday practice publication-title: JACC Heart Fail doi: 10.1016/j.jchf.2019.04.010 – volume: 6 start-page: 195 year: 2013 ident: 10.1007/s12350-023-03297-1_bib11 article-title: (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses publication-title: Circ Cardiovasc Imaging doi: 10.1161/CIRCIMAGING.112.000132 – volume: 14 start-page: 189 year: 2021 ident: 10.1007/s12350-023-03297-1_bib31 article-title: Reduction in CMR derived extracellular volume with patisiran indicates cardiac amyloid regression publication-title: JACC Cardiovasc Imaging doi: 10.1016/j.jcmg.2020.07.043 – volume: 13 start-page: 1368 year: 2020 ident: 10.1007/s12350-023-03297-1_bib12 article-title: How to image cardiac amyloidosis: a practical approach publication-title: JACC Cardiovasc Imaging doi: 10.1016/j.jcmg.2019.07.015 – volume: 22 start-page: 210 year: 2015 ident: 10.1007/s12350-023-03297-1_bib36 article-title: Usefulness of (99m)Tc-HMDP scintigraphy for the etiologic diagnosis and prognosis of cardiac amyloidosis publication-title: Amyloid doi: 10.3109/13506129.2015.1072089 – volume: 36 start-page: 322 year: 2020 ident: 10.1007/s12350-023-03297-1_bib1 article-title: CCS/CHFS joint position statement on the evaluation and management of patients with cardiac amyloidosis publication-title: Can J Cardiol doi: 10.1016/j.cjca.2019.12.034 – volume: 2 start-page: 17 year: 2018 ident: 10.1007/s12350-023-03297-1_bib29 article-title: Tc-HDP quantitative SPECT/CT in transthyretin cardiac amyloid and the development of a reference interval for myocardial uptake in the non-affected population publication-title: Eur J Hybrid Imaging doi: 10.1186/s41824-018-0035-1 – volume: 1 start-page: 880 year: 2016 ident: 10.1007/s12350-023-03297-1_bib15 article-title: Multicenter study of planar technetium 99m pyrophosphate cardiac imaging publication-title: JAMA Cardiol doi: 10.1001/jamacardio.2016.2839 – volume: 46 start-page: 1076 year: 2005 ident: 10.1007/s12350-023-03297-1_bib10 article-title: Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2005.05.073 – volume: 9 start-page: 211 year: 2009 ident: 10.1007/s12350-023-03297-1_bib16 article-title: Metandi: meta-analysis of diagnostic accuracy using hierarchical logistic regression publication-title: STATA J doi: 10.1177/1536867X0900900203 – volume: 14 start-page: 1221 year: 2021 ident: 10.1007/s12350-023-03297-1_bib9 article-title: Diagnosing transthyretin cardiac amyloidosis by technetium Tc 99m pyrophosphate: a test in evolution publication-title: JACC Cardiovasc Imaging doi: 10.1016/j.jcmg.2020.08.027 – volume: 11 start-page: 86 year: 2021 ident: 10.1007/s12350-023-03297-1_bib26 article-title: Quantitative SPECT/CT parameters of myocardial 99mTechnetium-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) uptake in suspected cardiac transthyretin amyloidosis publication-title: EJNMMI Res doi: 10.1186/s13550-021-00828-0 – volume: 379 start-page: 1007 year: 2018 ident: 10.1007/s12350-023-03297-1_bib3 article-title: Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy publication-title: N Engl J Med doi: 10.1056/NEJMoa1805689 – volume: 27 start-page: 28 year: 2020 ident: 10.1007/s12350-023-03297-1_bib43 article-title: Simultaneous Tc-99m PYP/Tl-201 dual-isotope SPECT myocardial imaging in patients with suspected cardiac amyloidosis publication-title: J Nucl Cardiol doi: 10.1007/s12350-019-01753-5 – ident: 10.1007/s12350-023-03297-1_bib23 doi: 10.1007/s12350-021-02563-4 – volume: 38 start-page: 470 year: 2011 ident: 10.1007/s12350-023-03297-1_bib32 article-title: Usefulness and limitations of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy publication-title: Eur J Nucl Med Mol Imaging doi: 10.1007/s00259-010-1642-7 – volume: 27 start-page: 371 year: 2020 ident: 10.1007/s12350-023-03297-1_bib40 article-title: 99mTechnetium pyrophosphate scintigraphy with cadmium zinc telluride cameras is a highly sensitive and specific imaging modality to diagnose transthyretin cardiac amyloidosis publication-title: J Nucl Cardiol doi: 10.1007/s12350-019-01831-8 – volume: 62 start-page: 716 year: 2021 ident: 10.1007/s12350-023-03297-1_bib25 article-title: Absolute quantitation of cardiac (99m)Tc-pyrophosphate using cadmium-zinc-telluride-based SPECT/CT publication-title: J Nucl Med doi: 10.2967/jnumed.120.247312 – ident: 10.1007/s12350-023-03297-1_bib44 doi: 10.1007/s12350-022-03180-5 – volume: 14 start-page: 1221 year: 2021 ident: 10.1007/s12350-023-03297-1_bib19 article-title: Diagnosing transthyretin cardiac amyloidosis by Technetium Tc 99m pyrophosphate publication-title: JACC – volume: 25 start-page: 181 year: 2018 ident: 10.1007/s12350-023-03297-1_bib18 article-title: Standardization of Technetium pyrophosphate imaging methodology to diagnose TTR cardiac amyloidosis publication-title: J Nucl Cardiol doi: 10.1007/s12350-016-0610-4 – volume: 65 start-page: 440 year: 2012 ident: 10.1007/s12350-023-03297-1_bib33 article-title: Role of cardiac scintigraphy with 99mTc-DPD in the differentiation of cardiac amyloidosis subtype publication-title: Rev Esp Cardiol doi: 10.1016/j.recesp.2011.12.015 – ident: 10.1007/s12350-023-03297-1_bib22 doi: 10.1007/s12350-021-02857-7 – ident: 10.1007/s12350-023-03297-1_bib24 doi: 10.1016/S0735-1097(21)02708-X – volume: 14 year: 2021 ident: 10.1007/s12350-023-03297-1_bib5 article-title: ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2—evidence base and standardized methods of imaging publication-title: Circ Cardiovasc Imaging – volume: 28 start-page: 90 year: 2021 ident: 10.1007/s12350-023-03297-1_bib39 article-title: Semi-quantitative indices of cardiac uptake in patients with suspected cardiac amyloidosis undergoing 99mTc-HMDP scintigraphy publication-title: J Nucl Cardiol doi: 10.1007/s12350-019-01643-w – volume: 37 start-page: 1826 year: 2015 ident: 10.1007/s12350-023-03297-1_bib21 article-title: Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness publication-title: Eur Heart J doi: 10.1093/eurheartj/ehv583 – volume: 26 start-page: 497 year: 2019 ident: 10.1007/s12350-023-03297-1_bib38 article-title: Accuracy of 99mTc-Hydroxymethylene diphosphonate scintigraphy for diagnosis of transthyretin cardiac amyloidosis publication-title: J Nucl Cardiol doi: 10.1007/s12350-017-0922-z – volume: 12 year: 2019 ident: 10.1007/s12350-023-03297-1_bib8 article-title: Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis publication-title: Circ Heart Fail doi: 10.1161/CIRCHEARTFAILURE.119.006075 – ident: 10.1007/s12350-023-03297-1_bib6 doi: 10.2967/jnumed.122.264311 – volume: 13 start-page: 1353 year: 2020 ident: 10.1007/s12350-023-03297-1_bib28 article-title: DPD quantification in cardiac amyloidosis publication-title: JACC Cardiovasc Imaging doi: 10.1016/j.jcmg.2020.03.020 – ident: 10.1007/s12350-023-03297-1_bib30 doi: 10.1007/s12350-021-02880-8 – volume: 26 start-page: 1183 year: 2017 ident: 10.1007/s12350-023-03297-1_bib37 article-title: The utility of (99m)Tc-DPD scintigraphy in the diagnosis of cardiac amyloidosis publication-title: Heart Lung Circ doi: 10.1016/j.hlc.2016.12.017 – ident: 10.1007/s12350-023-03297-1_bib27 doi: 10.1186/s40658-020-00342-7 – volume: 42 start-page: 1554 year: 2021 ident: 10.1007/s12350-023-03297-1_bib2 article-title: Diagnosis and treatment of cardiac amyloidosis publication-title: Eur Heart J doi: 10.1093/eurheartj/ehab072 – volume: 327 start-page: 557 year: 2003 ident: 10.1007/s12350-023-03297-1_bib14 article-title: Measuring inconsistency in meta-analyses publication-title: BMJ doi: 10.1136/bmj.327.7414.557 – volume: 30 start-page: 101 year: 2023 ident: 10.1007/s12350-023-03297-1_bib45 article-title: Quantitative (99m)Tc-DPD-SPECT/CT assessment of cardiac amyloidosis publication-title: J Nucl Cardiol doi: 10.1007/s12350-022-02960-3 – volume: 155 start-page: 529 year: 2011 ident: 10.1007/s12350-023-03297-1_bib13 article-title: QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies publication-title: Ann Intern Med doi: 10.7326/0003-4819-155-8-201110180-00009 – volume: 15 start-page: 1289 year: 2014 ident: 10.1007/s12350-023-03297-1_bib35 article-title: Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis publication-title: Eur Heart J Cardiovasc Imaging doi: 10.1093/ehjci/jeu107 – volume: 15 start-page: 179 year: 2020 ident: 10.1007/s12350-023-03297-1_bib4 article-title: A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis publication-title: J Rare Dis – volume: 27 start-page: 1802 year: 2020 ident: 10.1007/s12350-023-03297-1_bib42 article-title: Technetium pyrophosphate nuclear scintigraphy for cardiac amyloidosis: imaging at 1 vs 3 hours and planar vs SPECT/CT publication-title: J Nucl Cardiol doi: 10.1007/s12350-020-02139-8 |
SSID | ssj0009399 |
Score | 2.4742794 |
SecondaryResourceType | review_article |
Snippet | Bone scintigraphy imaging is frequently used to investigate patients with suspected transthyretin cardiac amyloidosis (ATTR-CM). However, the reported accuracy... Background Bone scintigraphy imaging is frequently used to investigate patients with suspected transthyretin cardiac amyloidosis (ATTR-CM). However, the... BackgroundBone scintigraphy imaging is frequently used to investigate patients with suspected transthyretin cardiac amyloidosis (ATTR-CM). However, the... |
SourceID | proquest pubmed crossref springer elsevier |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 2464 |
SubjectTerms | Accuracy Amyloid heart disease Amyloid Neuropathies, Familial - diagnostic imaging Amyloidosis Cardiology Cardiomyopathies - diagnostic imaging Humans Imaging Medical diagnosis Medicine Medicine & Public Health Meta analysis Nuclear Medicine Original Article Prealbumin Quantitative analysis Radiology Radionuclide Imaging Scintigraphy SPECT Systematic review Tomography, X-Ray Computed |
Title | Diagnostic accuracy of bone scintigraphy imaging for transthyretin cardiac amyloidosis: systematic review and meta-analysis |
URI | https://dx.doi.org/10.1007/s12350-023-03297-1 https://link.springer.com/article/10.1007/s12350-023-03297-1 https://www.ncbi.nlm.nih.gov/pubmed/37226006 https://www.proquest.com/docview/2894439024 https://www.proquest.com/docview/2819276538 |
Volume | 30 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVLSH databaseName: Elsevier Journals customDbUrl: mediaType: online eissn: 1532-6551 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0009399 issn: 1071-3581 databaseCode: AKRWK dateStart: 19950101 isFulltext: true providerName: Library Specific Holdings – providerCode: PRVLSH databaseName: SpringerLink Journals customDbUrl: mediaType: online eissn: 1532-6551 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0009399 issn: 1071-3581 databaseCode: AFBBN dateStart: 19970101 isFulltext: true providerName: Library Specific Holdings – providerCode: PRVAVX databaseName: SpringerLINK - Czech Republic Consortium customDbUrl: eissn: 1532-6551 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0009399 issn: 1071-3581 databaseCode: AGYKE dateStart: 19970101 isFulltext: true titleUrlDefault: http://link.springer.com providerName: Springer Nature – providerCode: PRVAVX databaseName: SpringerLink Journals (ICM) customDbUrl: eissn: 1532-6551 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0009399 issn: 1071-3581 databaseCode: U2A dateStart: 19970101 isFulltext: true titleUrlDefault: http://www.springerlink.com/journals/ providerName: Springer Nature |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEB7BVkJcKG9SyspI3MBVYidxwm1Lu1Sg9sRK5WT5FWlFN0Hd7KHw5xknzkaiD6nKJYrtaOLMeGY0M98AfNAs0ZY7Q4VvHYAar6Kly1NqBIudzbjWHWT-6Vl-ski_nWfnoShsPWS7DyHJ7qQei90Yz2KKOobGnJWCos-zk3kHZQI7s68_vx-PYLu86xuJnk1CPb5XKJa5-S23KaTrBue1YGmng-a7sBio71NPfh1sWn1g_vwH7Hjfz3sKT4JRSmY9Fz2DB65-Do9OQ9j9Bfw96hPycJgoYzaXylyRpiK6qR1BHVq3yx74mixXXdcjgqYwab0aRD7wdZI1MR0r4vrV1UWztM16uf5MRhxp0tfQEFVbsnKtoiqgpbyExfz4x5cTGro2UIOuTEttZXOh0Q-JqyIvWKUsXvigjDWr0sLGaaJT5VFteKGKJK3KItbopJu8KpLcWf4KJjWS_waI46lRLtO85HhX5qV1ieFMC6OFLoSJIBl-nTQB0tx31riQIxiz31WJuyq7XZVJBB-3a373gB53zs4GjpDBJOlNDYka5851-wP7yHAorCX6tilKA1pFEbzfDqM4-xiNql2z8XPQ5BY5qqEIXvdstyWTC-bbCeQRfBpYaHz57bTs3W_6W3jMPBd2KTv7MGkvN-4dGl6tnqKczQ8Pz6ZB3qbwcMFm_wCRcySS |
linkProvider | Springer Nature |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEB6hrQRceFNSChiJG7hKYidxuFXQstBuT12pnCy_Iq3oJqibPbT8ecaJs5EorVTlEsV2NHHG_mY0nm8APug00ZY5QwtfOgARr6Klyzk1RRo7mzGtO8r82Uk-nfMfZ9lZSApbDafdh5Bkt1OPyW4py2KKGENjlpYFRZ9niydC8Als7X_7eXQwku2yrm4kejYJ9fxeIVnm_2-5CZCuG5zXgqUdBh0-hvkgfX_05NfeutV75uofYse7ft4TeBSMUrLfa9FTuOfqZ3B_FsLuz-HP1_5AHjYTZcz6QplL0lREN7UjiKF1u-iJr8li2VU9ImgKk9bDIOqBz5OsielUEccvL8-bhW1Wi9VnMvJIkz6HhqjakqVrFVWBLeUFzA8PTr9MaajaQA26Mi21lc0LjX5IXIlcpJWyeOGDMtZpxYWNeaK58qw2TCiR8KoUsUYn3eSVSHJn2UuY1Cj-KyCOcaNcplnJ8K7MS-sSw1JdGF1oUZgIkuHXSRMozX1ljXM5kjH7WZU4q7KbVZlE8HEz5ndP6HFr72zQCBlMkt7UkIg4t47bHdRHhk1hJdG35bga0CqK4P2mGZezj9Go2jVr3wdN7iJHGIpgu1e7jZisSH05gTyCT4MKjS-_WZadu3V_Bw-mp7Njefz95Og1PEy9RnbHd3Zh0l6s3Rs0wlr9Nqy5v3XDJR4 |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1La9wwEBYlhdBLSdO0dZomKvTWitiSLNm9hSZLHk3IoQu5CT1hIesNWe-h9M93JNvrQppA8MVYD4RnxPcN0nyD0BdDC-OYt0TG0gGAeIHUXnBiJc29K5kxSTL_8kqcTvn5TXnzTxZ_uu0-HEl2OQ1RpalpD-9cOBwT3ygrcwJ4Q3JGa0kg_nnJAatj-DWlR6PsLksVJCHGKUhU-urTZv4_x2PQ9JB6Pjg2TWg02UKvexqJjzq7v0EvfLONNi_7g_K36M9xd4UOmrG2dnWv7W-8CNgsGo8B9Zp21klV49k81SnCQF5xG4ELLBczGxtsk_PA-DkE9TO3WM6W3_Go_Iy7rBesG4fnvtVE9_omO2g6Ofn145T0dRaIheCjJS44IQ1EDnmoREWDdvDAhzo3NPDK5bwwXEcdGlbpquChrnIDYbUVoSqEd-wd2mhg-R8Q9oxb7UvDagZvtaidLyyjRlojTSVthorhFyvbi5DHWhi3apRPjmZRYBaVzKKKDH1dj7nrJDie7F0OllM9iejIgQKMeHLc3mBm1W_jpYJolIP_Ao_J0Od1M2zAeKqiG79YxT5AkqUA4MjQ-8491stkksYCACJD3wZ_GSd_fC27z-t-gDavjyfq59nVxUf0ikaPTvdt9tBGe7_yn4A1tWY_bYy_KMAMbA |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Diagnostic+accuracy+of+bone+scintigraphy+imaging+for+transthyretin+cardiac+amyloidosis%3A+systematic+review+and+meta-analysis&rft.jtitle=Journal+of+nuclear+cardiology&rft.au=Ahluwalia%2C+Nanki&rft.au=Roshankar%2C+Golnaz&rft.au=Draycott%2C+Logan&rft.au=Jimenez-Zepeda%2C+Victor&rft.date=2023-12-01&rft.eissn=1532-6551&rft.volume=30&rft.issue=6&rft.spage=2464&rft_id=info:doi/10.1007%2Fs12350-023-03297-1&rft_id=info%3Apmid%2F37226006&rft.externalDocID=37226006 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1071-3581&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1071-3581&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1071-3581&client=summon |